Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
ORTHO CYCLEN-21 is an oral contraceptive tablet containing norgestimate and ethinyl estradiol, approved in 1989 as a combined hormonal birth control product. It prevents pregnancy through ovulation suppression and cervical mucus thickening. The 21-day formulation requires a 7-day hormone-free interval for menstruation.
Product approaching loss of exclusivity with low linked job activity, suggesting a mature franchise with limited team expansion opportunities.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Zero linked job openings and LOE approaching status indicate this is a stable-maintenance role with limited growth trajectory. Career development on ORTHO CYCLEN-21 typically involves defensive market strategies and organizational efficiency rather than innovation or market expansion.
Worked on ORTHO CYCLEN-21 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.